No registrations found.
ID
Source
Brief title
Health condition
Bladder cancer
Sponsors and support
Intervention
Outcome measures
Primary outcome
Identification rate, defined as the proportion of patients in whom sentinel and non-sentinel lymph nodes was identified percutaneously with the fluorescent signal of ICG:HSA.
Secondary outcome
1. Median number of lymph nodes identified with ICG:HSA;
2. Sensitivity: percentage of patients in whom fluorescent lymph nodes were identified of the total patients with identified sentinel lymph nodes by standard SNB technique;
3. signal-to-background ratio.
Background summary
A new and still experimental lymphadenectomy approach in bladder cancer is to identify, remove, and analyze a sentinel lymph node (SLN) or nodes. Fluorescent imaging using near-infrared probes is an innovative technique to directly visualize lymphatic pathways and lymph nodes. We hypothesize that an ICG coupled to human serum albumin would provide a highly sensitive, high-resolution image of SLNs.
Study objective
Fluorescent near-infrared imaging can accurately detect lymph nodes non-invasively during SLN mapping in bladder cancer patients.
Study design
The primary and secondary outcomes will be assessed during surgery and pathological assessment.
Intervention
Standard lymphadectomy will be performed. Before surgery, the near-infrared dye ICG:HSA will be injected and lymphatic pathways and lymph nodes will be visualized non-invasively using our experimental camerasystem.
Department of Surgical Oncology,
P.O. Box 9600
C.J.H. Velde, van de
Leiden 2300 RC
The Netherlands
+31 (0)71 5262309
c.j.h.van_de_velde@lumc.nl
Department of Surgical Oncology,
P.O. Box 9600
C.J.H. Velde, van de
Leiden 2300 RC
The Netherlands
+31 (0)71 5262309
c.j.h.van_de_velde@lumc.nl
Inclusion criteria
Bladder cancer patients planned to undergo a wide local excision and lymphadenectomy.
Exclusion criteria
1. History of allergy to iodine, shellfish, indocyanine green or human serum albumin;
2. Pregnancy;
3. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL3477 |
| NTR-old | NTR3657 |
| Other | METC LUMC : P09.001 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |